Spots Global Cancer Trial Database for An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)
Official Title: Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL)
Study ID: NCT02782845
Conditions
Study Description
Brief Summary: This study will assess the prophylactic effect of pegfilgrastim (Neulastim) on febrile and/or Grade IV neutropenia in participants receiving chemotherapy (CT) or immunochemotherapy (ICT) as first or second line treatment for NHL. Pegfilgrastim will be administered at a fixed dose of 6 milligrams (mg) subcutaneously 24 hours after the last dose of CT or ICT in each treatment cycle.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Bogota, , Colombia
, Chihuahua, , Mexico
, Chihuahua, , Mexico
, Estado de Mexico, , Mexico
, Guadalajara, , Mexico
, Leon, , Mexico
, Leon, , Mexico
, Mexico City, , Mexico
, Mexico City, , Mexico
, Mexico City, , Mexico
, Mexico City, , Mexico
, Mexico City, , Mexico
, Mexico City, , Mexico
, Obregon, , Mexico
, Puebla, , Mexico
, Queretaro, , Mexico
, Tepic, , Mexico
, Toluca, , Mexico
, Veracruz, , Mexico
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
